List of adverse effects of nilotinib
Nilotinib is a tyrosine kinase inhibitor used primarily in the treatment of chronic myelogenous leukemia (CML). Like all medications, nilotinib can cause a range of adverse effects, which can vary in severity from mild to life-threatening. This article aims to provide a comprehensive list of the known adverse effects associated with nilotinib, categorized by their frequency and severity.
Common Adverse Effects[edit | edit source]
Common adverse effects are those that occur in more than 1% of patients taking nilotinib. These include:
- Fatigue
- Headache
- Nausea
- Pruritus (itching)
- Rash
- Muscle cramps
- Joint pain
- Abdominal pain
- Constipation
- Diarrhea
Uncommon Adverse Effects[edit | edit source]
Uncommon adverse effects occur in less than 1% but more than 0.1% of patients. These can include:
- Elevated bilirubin levels
- Hepatotoxicity (liver damage)
- Pancreatitis
- Hyperglycemia (high blood sugar)
- Electrolyte imbalance
- QT prolongation (a type of heart rhythm problem)
Rare Adverse Effects[edit | edit source]
Rare adverse effects are those that occur in less than 0.1% of patients. These can be severe and include:
- Tumor lysis syndrome
- Hepatic failure
- Interstitial lung disease
- Peripheral artery occlusive disease
- Myocardial infarction (heart attack)
- Stroke
Life-Threatening Adverse Effects[edit | edit source]
Some adverse effects of nilotinib can be life-threatening and require immediate medical attention. These include:
- Anaphylaxis (severe allergic reaction)
- Severe hepatotoxicity
- Cardiac arrest
- Severe QT prolongation
Monitoring and Management[edit | edit source]
Patients receiving nilotinib should be closely monitored for the development of adverse effects. Monitoring may include regular blood tests to check liver function, electrolyte levels, and blood cell counts, as well as heart monitoring for signs of QT prolongation. Management of adverse effects may involve dose adjustment, temporary discontinuation of nilotinib, or switching to an alternative therapy.
Conclusion[edit | edit source]
While nilotinib is an effective treatment for CML, it is associated with a wide range of adverse effects. Patients and healthcare providers should work closely together to monitor for these effects and manage them appropriately.
This list is incomplete; you can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD